Locally Advanced Prostate Cancer
10
6
6
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (10)
Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions
STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
Improved Robotic-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Bladder Suspension and Preliminary Outcomes
MRI Guided Transurethral HIFU for Various Prostate Diseases
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
TNFerade Biologic to Treat Locally Advanced Prostate Cancer
Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer